EBI3 as a Diagnostic Marker for Lymphomas
Author Information
Author(s): Gonin Julie, Larousserie Frédérique, Bastard Christian, Picquenot Jean-Michel, Couturier Jérôme, Radford-Weiss Isabelle, Dietrich Céline, Brousse Nicole, Vacher-Lavenu Marie-Cécile, Devergne Odile
Primary Institution: CNRS UMR 8147, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Hypothesis
Can EBI3 expression differentiate between Burkitt lymphoma and diffuse large B-cell lymphoma?
Conclusion
EBI3 is not expressed in Burkitt lymphoma but is expressed in a significant proportion of diffuse large B-cell lymphoma cases, making it a potential diagnostic marker.
Supporting Evidence
- EBI3 was not expressed in EBV-positive or -negative Burkitt lymphoma cases.
- Over 30% of tumoral cells in nearly 80% of diffuse large B-cell lymphoma cases expressed EBI3.
- c-myc overexpression represses EBI3 expression.
- EBI3 immunohistochemistry could help discriminate between Burkitt lymphoma and diffuse large B-cell lymphoma.
Takeaway
This study found that a protein called EBI3 is not found in one type of lymphoma but is present in another type, which can help doctors tell them apart.
Methodology
The study analyzed gene expression data and performed immunohistochemical analysis on tumor biopsies from 184 cases of aggressive B-cell lymphomas.
Potential Biases
Potential bias in sample selection and classification of lymphoma types.
Limitations
The study is limited to the analysis of specific tumor types and may not generalize to all lymphomas.
Participant Demographics
The study included cases diagnosed between 1987 and 2009 from multiple hospitals in France.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website